ERBB2 and neoplasm: Future trials will need to incorporate current practices, including neoadjuvant treatment, anthracycline-free chemotherapy backbones, and dual anti-HER2 therapy, with a greater emphasis on personalized treatment driven by clinical biomarkers and tumor profiling, in addition to traditional clinicopathologic risk stratification.